ATE472554T1 - Aminosäureaustauschmutanten von interleukin 13 - Google Patents
Aminosäureaustauschmutanten von interleukin 13Info
- Publication number
- ATE472554T1 ATE472554T1 AT01968131T AT01968131T ATE472554T1 AT E472554 T1 ATE472554 T1 AT E472554T1 AT 01968131 T AT01968131 T AT 01968131T AT 01968131 T AT01968131 T AT 01968131T AT E472554 T1 ATE472554 T1 AT E472554T1
- Authority
- AT
- Austria
- Prior art keywords
- amino acid
- interleukin
- hil13
- acid exchange
- acid residues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22919400P | 2000-08-30 | 2000-08-30 | |
| PCT/US2001/026558 WO2002018422A1 (en) | 2000-08-30 | 2001-08-24 | Amino acid substitution mutants of interleukin 13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE472554T1 true ATE472554T1 (de) | 2010-07-15 |
Family
ID=22860182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01968131T ATE472554T1 (de) | 2000-08-30 | 2001-08-24 | Aminosäureaustauschmutanten von interleukin 13 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1315742B1 (de) |
| JP (1) | JP4863150B2 (de) |
| AT (1) | ATE472554T1 (de) |
| AU (1) | AU2001288405B8 (de) |
| DE (1) | DE60142479D1 (de) |
| WO (1) | WO2002018422A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005042028A2 (en) * | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| ES2412005T3 (es) * | 2005-04-15 | 2013-07-09 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Tratamiento y prevención de la enfermedad intestinal inflamatoria que implica IL-13 y células NKT |
| EP2850093B1 (de) * | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutische il-13-polypeptide |
| IN2015KN00329A (de) | 2012-08-09 | 2015-07-10 | Univ Leland Stanford Junior | |
| CN105764926A (zh) | 2013-09-24 | 2016-07-13 | 梅迪塞纳医疗股份有限公司 | 白介素-4受体结合融合蛋白及其应用 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| EP4276114A3 (de) | 2016-03-07 | 2024-02-21 | Vib Vzw | Einzeldomänenantikörper gegen cd20 |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| JP7204643B2 (ja) | 2016-10-24 | 2023-01-16 | オリオニス バイオサイエンシズ ビーブイ | 標的変異インターフェロン－ガンマおよびその使用 |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| CA3078434A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| US12404497B2 (en) | 2018-06-01 | 2025-09-02 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof |
| CA3102097A1 (en) | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| WO2024236167A1 (en) | 2023-05-17 | 2024-11-21 | Morphosys Ag | Il-13 receptor alpha 2 binding polypeptides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US6028176A (en) * | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| JP2003511019A (ja) * | 1999-10-06 | 2003-03-25 | ザ ペン ステート リサーチ ファウンデーション | Ｉｌ１３変異体 |
| CA2404763A1 (en) * | 1999-11-11 | 2001-05-17 | Raj K. Puri | Mutated il-13 molecules and their uses |
-
2001
- 2001-08-24 JP JP2002523936A patent/JP4863150B2/ja not_active Expired - Fee Related
- 2001-08-24 WO PCT/US2001/026558 patent/WO2002018422A1/en not_active Ceased
- 2001-08-24 EP EP01968131A patent/EP1315742B1/de not_active Expired - Lifetime
- 2001-08-24 AT AT01968131T patent/ATE472554T1/de not_active IP Right Cessation
- 2001-08-24 AU AU2001288405A patent/AU2001288405B8/en not_active Ceased
- 2001-08-24 DE DE60142479T patent/DE60142479D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1315742A1 (de) | 2003-06-04 |
| EP1315742A4 (de) | 2004-08-11 |
| JP2004507264A (ja) | 2004-03-11 |
| WO2002018422A1 (en) | 2002-03-07 |
| AU2001288405B8 (en) | 2007-06-14 |
| EP1315742B1 (de) | 2010-06-30 |
| AU2001288405B2 (en) | 2007-05-03 |
| DE60142479D1 (de) | 2010-08-12 |
| JP4863150B2 (ja) | 2012-01-25 |
| AU8840501A (en) | 2002-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60142479D1 (de) | Aminosäureaustauschmutanten von interleukin 13 | |
| CY1111006T1 (el) | Εκριμματαση ασθενειας alzheimer | |
| DE69533923D1 (de) | Cytokinin-designiertes lerk-5 | |
| ATE293696T1 (de) | Mutierte alpha-amylase enzyme mit erhöhter stabilität | |
| CY1108998T1 (el) | Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις | |
| ATE364704T1 (de) | Mutanten von op-1 | |
| BRPI0207933B8 (pt) | polipeptídeo mutante de interleucina-18 e composição farmacêutica | |
| CY1109230T1 (el) | Ισομεραση συζευγμενου λινελαϊκου οξεος και μια διαδικασια για την παρασκευη συζευγμενου λινελαϊκου οξεος | |
| NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
| ES8705467A1 (es) | Un procedimiento para producir la proteina apoacuorina | |
| ATE270337T1 (de) | Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen | |
| PT762901E (pt) | Peptidos marcados com tecnecio-99m para imagiologia. | |
| PE20010694A1 (es) | Plasmido autonomamente reproducible en bacterias corineformes | |
| EA199900869A1 (ru) | Цитокин-подобный фактор 7 млекопитающих | |
| ATE294855T1 (de) | Rna polymerase mutanten mit erhöhter thermostabilität | |
| DE60017141D1 (de) | Replikationskompetente anti-tumor vektoren | |
| DE60109430D1 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
| PT1025245E (pt) | Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes | |
| ATE337336T1 (de) | Nukleinsäuren, die für stichodactylidae chromoproteine kodieren | |
| ES2185002T3 (es) | Metodos y composiciones para detectar mutaciones por empalme de la deshidrogenasa de dihidro-pirimidina. | |
| ATE141415T1 (de) | Konjugate von antikörpern mit variablen domänen | |
| ATE356831T1 (de) | Neuer galaninrezeptor | |
| AU2001238064A1 (en) | 18477, a human protein kinase and uses therefor | |
| WO2000037645A3 (en) | Cell cycle nucleic acids, polypeptides and uses thereof | |
| DE69103629D1 (de) | Pendelvektor für die entwicklung von einem rekombinanten bacillus thuringiensis-stamm. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |